Status:
COMPLETED
Curative D2 vs D1 Lymphadenectomy in Operable Gastric Carcinoma
Lead Sponsor:
University of Alexandria
Conditions:
Gastric Cancer
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Gastric carcinoma is the second most common cause of cancer-related deaths and its main treatment modality if potentially curable is surgery but the optimal surgical resection is controversial. The ai...
Detailed Description
80 consecutive patients with potentially operable gastric carcinoma were randomized via concealed envelopes into 2 groups (each included 40 patients), group I managed by radical gastrectomy with D1 ly...
Eligibility Criteria
Inclusion
- Histologically confirmed gastric carcinoma
- Potentially operable gastric carcinoma without evidence of distant metastasis
Exclusion
- Complicated gastric cancer (obstructed or perforated)
- Locally irresectable tumor
- Previous or coexisting cancer
- Prior gastric surgery or neoadjuvant chemotherapy
- Contraindication for major surgery
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04340440
Start Date
December 1 2014
End Date
February 1 2020
Last Update
April 10 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.